Renal denervation has made a striking comeback after early controversy, but is the evidence strong enough to change your practice? High-stakes cases of resistant hypertension are put before a judge's panel of a nephrologist and cardiologist, each bringing a sharply different perspective on whether to proceed. The audience votes on management before and after the panel deliberates openly, exposing the fault lines between enthusiasm for a novel tool and demands for a more robust evidence base. Does denervation have a place in 2027, or does the bar remain unmet?
| Time | Session |
|---|---|
|
16:15
16:35
|
Against renal denervation
Swapnil Hiremath
Speaker
|
|
16:35
16:55
|
For renal denervation
Jiguang Wang
Speaker
|
|
16:55
17:15
|
Q&A
|